Chris DeMuth Jr.'s  Instablog

Chris DeMuth Jr.
  • on Technology
  • on Services
  • on Conglomerates
Send Message
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for... More
My blog:
Rangeley Capital on Harvest
My book:
Rangeley Capital Best Investment Ideas
  • Do Neurologists Want A New Therapy For MS? 0 comments
    Jan 16, 2014 5:33 PM | about stocks: GCVRZ, SNY

    Recently, top MS doctor Dr. Samuel F. Hunter weighed in on Lemtrada on his blog which focuses on current interests in neurology healthcare (the emphasis is mine),

    So we end up in December. The FDA is on the "Naughty" list this year yet again for its handling of the biggest game-changing medication ever for MS. They managed to find a panel of physicians who were unbiased to review the research data to decide about approval for MS. Unfortunately, these were the most ignorant group of physicians ever assembled to review an MS drug application. 20 years of research data. Thousands of patient years. Absolute unbelievable ignorance. They voted the trials were inadequate and poorly designed (not a single expert believes this). The medication was twice as effective as Rebif, a standard of care medication. It was so much better than Rebif anyway you would have thought that Rebif was an inactive medication. Yet they voted it should be approved (they were not following the rules). We'll see if there is someone wise enough at FDA to clean this mess up. This after the poor company waited TWO YEARS for the FDA to address the application. Another reason drugs cost too much…the FDA is slow. Not understaffed, just really really slow and lazy about following its own rules.

    We really really need alemtuzumab. Just like you need a chainsaw when a big tree falls in your yard. This is the drug for the heavy lifting in MS which we have needed for years. It ACTUALLY MAKES PEOPLE BETTER FOR YEARS. More about this when the drug nears approval.

    Dr. Samuel F. Hunter, M.D., Ph.D. practices at Brain and Nerve Neurology in Franklin, Tennessee, and directs the Advanced Neurosciences Institute and the NeuroNexus Neurology Education and Research Center.

    Here I quote his blog extensively to offer a sense of what MS specialists think about Lemtrada. Given that the FDA review process - which resulted in last month's rejection - excluded MS specialists from the consideration of this MS therapy, it may be useful to include them in the ongoing appeal. What choices do MS patients want? What choices do their doctors want?

    Stocks: GCVRZ, SNY
Back To Chris DeMuth Jr.'s Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Most Commented
  1. Archived GCVRZ Forum ( Comments)
  2. GCVRZ Forum Archive ( Comments)
  3. Event Driven Q&A Forum ( Comments)
  4. GPT Forum ( Comments)
  5. Shorts Forum ( Comments)
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.